Terry Kohler - Nov 14, 2023 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
Chief Financial Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
VRCA
Transactions as of
Nov 14, 2023
Transactions value $
-$82,671
Form type
4
Date filed
11/16/2023, 04:34 PM
Previous filing
Aug 28, 2023
Next filing
Mar 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRCA Common Stock Sale -$54.1K -18.5K -29.52% $2.93 44K Nov 14, 2023 Direct F1, F2
transaction VRCA Common Stock Sale -$28.6K -9.63K -21.87% $2.97 34.4K Nov 15, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for RSUs that vested on August 24, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.95 to $3.00 inclusive.